United Therapeutics Corp. (UTHR)
492.21
-20.49
(-4.00%)
USD |
NASDAQ |
Sep 02, 16:00
492.21
0.00 (0.00%)
After-Hours: 17:53
United Therapeutics Research and Development Expense (TTM) : 551.50M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 551.50M |
| March 31, 2026 | 539.20M |
| December 31, 2025 | 550.00M |
| September 30, 2025 | 544.30M |
| June 30, 2025 | 520.30M |
| March 31, 2025 | 525.90M |
| December 31, 2024 | 481.00M |
| September 30, 2024 | 498.60M |
| June 30, 2024 | 479.80M |
| March 31, 2024 | 429.20M |
| December 31, 2023 | 408.00M |
| September 30, 2023 | 350.50M |
| June 30, 2023 | 331.90M |
| March 31, 2023 | 336.80M |
| December 31, 2022 | 322.90M |
| September 30, 2022 | 311.90M |
| June 30, 2022 | 323.80M |
| March 31, 2022 | 304.20M |
| December 31, 2021 | 410.00M |
| September 30, 2021 | 453.20M |
| June 30, 2021 | 443.90M |
| March 31, 2021 | 459.30M |
| December 31, 2020 | 357.70M |
| September 30, 2020 | 345.20M |
| June 30, 2020 | 362.20M |
| Date | Value |
|---|---|
| March 31, 2020 | 349.60M |
| December 31, 2019 | 373.80M |
| September 30, 2019 | 399.00M |
| June 30, 2019 | 414.40M |
| March 31, 2019 | 419.60M |
| December 31, 2018 | 357.90M |
| September 30, 2018 | 332.70M |
| June 30, 2018 | 286.60M |
| March 31, 2018 | 264.10M |
| December 31, 2017 | 264.60M |
| September 30, 2017 | 217.90M |
| June 30, 2017 | 208.80M |
| March 31, 2017 | 184.20M |
| December 31, 2016 | 147.60M |
| September 30, 2016 | 156.65M |
| June 30, 2016 | 116.15M |
| March 31, 2016 | 130.36M |
| December 31, 2015 | 240.97M |
| September 30, 2015 | 236.51M |
| June 30, 2015 | 349.98M |
| March 31, 2015 | 340.31M |
| December 31, 2014 | 242.55M |
| September 30, 2014 | 292.62M |
| June 30, 2014 | 246.49M |
| March 31, 2014 | 261.37M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Liquidia Corp. | 54.95M |
| MannKind Corp. | 76.88M |
| Vertex Pharmaceuticals, Inc. | 3.907B |
| Savara, Inc. | 86.84M |
| Exelixis, Inc. | 824.32M |